Analyst Coverage

Analyst Coverage

The following research analysts cover Destiny Pharma.

Mark Brewer, finnCap +44(0)20 7220 0500
Andy Smith, Equity Development +44(0)20 7065 2690
Karl Keegan, Singer Capital Markets +44(0)20 7496 3187

 

Please click on links below to access coverage published:

finnCap finnCap

Analyst research from finnCap can be obtained by registering on the link above

19 July 2022 – Positive FDA feedback on pivotal US trial design
5 July 2022 – New clinical study with XF-73 in oral mucositis prevention

Equity Development Equity Development

19 July 2022 – Greater regulatory clarity given
5 July 2022 – A useful addition to XF-73’s profile

Destiny Pharma - Proactive Proactive Investors

For further commentary and interviews, please visit the Destiny Pharma page at Proactive Investors on the link above

Destiny Pharma Vox Markets VOX Markets

For further commentary and interviews, please visit the Destiny Pharma page at Vox Markets on the link above